文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

诺瓦瓦克斯新冠疫苗(NVX-CoV2373)的获益-风险评估

Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
PubMed 文献 · Vaccine · 2024-03-16

该获益-风险评估旨在判断接种NVX-CoV2373的获益是否超过心肌炎/心包炎风险,使用该疫苗临床研究中的心肌炎/心包炎病例数据、2023年初mRNA新冠疫苗针对主要SARS-CoV-2毒株有效性的真实世界数据及美国近期COVID-19疾病负担数据。分析显示,每10万接种者中估计预防1805例COVID-19病例,而估计增加5.3例心肌炎/心包炎病例,预防的COVID-19住院和死亡数也大于疫苗相关心肌炎/心包炎住院和死亡数,表明NVX-CoV2373具有正向获益-风险平衡。

要点

  • 每10万接种者中,NVX-CoV2373估计预防1805例COVID-19病例,估计增加5.3例心肌炎/心包炎病例。
  • 预防的COVID-19住院和死亡数大于疫苗相关心肌炎/心包炎住院和死亡数。
  • 分析表明NVX-CoV2373具有正向获益-风险平衡。

核心结论

  • 分析表明NVX-CoV2373具有正向获益-风险平衡。

研究设计与样本

  • 对NVX-CoV2373进行获益-风险评估,使用该疫苗临床研究中的心肌炎/心包炎病例数据、2023年初mRNA新冠疫苗针对主要SARS-CoV-2毒株有效性的真实世界数据及美国近期COVID-19疾病负担数据。

主要发现

  • 每10万接种者中,NVX-CoV2373估计预防1805例COVID-19病例,而估计增加5.3例心肌炎/心包炎病例。
  • 预防的COVID-19住院和死亡数也大于疫苗相关心肌炎/心包炎住院和死亡数。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A benefit-risk assessment of NVX-CoV2373, a vaccine to prevent COVID-19, was conducted to determine if the benefits of vaccination outweigh the risks of myocarditis/pericarditis. This analysis used data on myocarditis/pericarditis cases observed in the NVX-CoV2373 clinical studies, real-world data of mRNA COVID vaccine effectiveness against predominant SARS-CoV-2 strains in early 2023, and recent COVID-19 burden of disease data from the United States. The benefits of NVX-CoV2373 vaccination were estimated as the number of COVID-19 cases, hospitalizations, and deaths prevented. The risks of myocarditis/pericarditis cases and related hospitalizations and deaths occurring within 7 days of vaccination were also estimated. In our analysis, vaccination with NVX-CoV2373, per 100,000 vaccinated, resulted in an estimated 1805 COVID-19 cases prevented compared with an estimated 5.3 excess myocarditis/pericarditis cases. The number of COVID-19 hospitalizations and deaths prevented were also greater than vaccine-associated myocarditis/pericarditis hospitalizations and deaths. Our analysis indicates a positive benefit-risk balance for NVX-CoV2373.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Fix J, Christopher Mast T, Smith K, et al. Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373). Vaccine. 2024. PMID: 38494410. doi:10.1016/j.vaccine.2024.03.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。